Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | CDC25B | P30305 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24859248 | 0.78 | — | — | |
| SCHEMBL21288093 | 0.77 | MEN1 (0.35) | MEN1CYP3A4ALOX15KMT2ALMNA | |
| SCHEMBL12016491 | 0.74 | LMNA (0.38) | MEN1CYP3A4ALOX15KMT2ALMNA | |
| SCHEMBL7776935 | 0.73 | — | — | |
| SCHEMBL15745492 | 0.72 | LMNA (0.42) | MEN1CYP3A4ALOX15KMT2ALMNA | |
| SCHEMBL19901393 | 0.72 | LMNA (0.56) | MEN1CYP3A4ALOX15KMT2ALMNA | |
| SCHEMBL20349749 | 0.70 | LMNA (0.40) | MEN1CYP3A4ALOX15KMT2ALMNA | |
| SCHEMBL24031315 | 0.70 | LMNA (0.40) | MEN1CYP3A4ALOX15KMT2ALMNA | |
| SCHEMBL22018637 | 0.70 | LMNA (0.40) | MEN1CYP3A4ALOX15KMT2ALMNA | |
| SCHEMBL23696194 | 0.70 | LMNA (0.40) | MEN1CYP3A4ALOX15KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159491-A1 | Antimicrobial Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159491-A1 | Antimicrobial Compounds and Methods | MPO, NISCH, RPN2 | MEN1 4216/4885CYP3A4 2721/4885ALOX15 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.